BI wants to 'own' lung therapy space as India-priced afatinib debuts
This article was originally published in Scrip
Executive Summary
"We want to own the lung cancer therapy space," is how Boehringer Ingelheim (BI) India's managing director Sharad Tyagi refers to the family-owned German multinational's ambitions in the segment with the introduction of its first oncology product, afatinib, on the domestic market.
You may also be interested in...
BI India’s First Woman MD May Have To Hit The Ground Running
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.
Cut-Price Generics Set To Challenge Boehringer’s Nintedanib In India
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.